ARTICLE | Company News

Aetna latest to favor Gilead's HCV therapies

January 17, 2015 4:39 AM UTC

Aetna Inc. (NYSE:AET) said Friday that it made Harvoni ledipasvir/ sofosbuvir from Gilead Sciences Inc. (NASDAQ:GILD) its preferred drug to treat HCV genotype 1 and the company's Sovaldi sofosbuvir its preferred treatment for genotypes 2, 3 and 4. Aetna will offer Viekira Pak paritaprevir/ ritonavir/ ombitasvir/ dasabuvir from AbbVie Inc. (NYSE:ABBV) only to patients who fail treatment with Gilead's drugs.

Aetna said Gilead agreed to provide the drugs at an undisclosed discount. Aetna, which limits access based on liver fibrosis scores of F3 and F4, said its clinical restrictions related to disease severity will remain in place. ...